Latest News from ASCO in Action

Latest News from ASCO in Action

January 29, 2015

On January 29, 2015, the U. S. Food and Drug Administration approved ibrutinib (Imbruvica® Capsules, Pharmacyclics, Inc.) for the treatment of patients with Waldenstrom's macroglobulinemia (WM).

January 29, 2015

The U.S. Department of Health and Human Services announced its intention to shift Medicare away from the current fee-for-service model and toward a system that pays providers based on the quality—rather than the quantity—of care they provide. ASCO supports the shift toward alternative payment models; as it aligns with ASCO's own proposal to reform payment for oncology care, which would restructure the way oncologists are reimbursed in the United States by focusing payment on the full range of patient services oncologists provide, while incentivizing high-quality, patient-centered care.

January 27, 2015
The House Energy and Commerce Committee released a discussion document outlining specific proposals for the 21st Century Cures initiative, which aims to accelerate the pace of cures in the United States. The document was released to solicit input from patients, innovators, researchers, care givers, and other experts. ASCO has weighed in heavily since the initiative's launch, and the society is thoroughly reviewing and preparing comments on the proposals outlined in the discussion document.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.